← All trials
NCT06179732
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 5, 2023
- Primary completion
- Jan 26, 2024
- Completion date
- Jan 26, 2024
- First posted
- Dec 22, 2023
- Last posted
- Dec 22, 2023
- Enrollment
- 2400
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- The Mentor InitiativeLead sponsor
- University of LiverpoolCollaborator
- The Mentor InitiativeOverall official - principal investigator
- The Mentor InitiativeOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.